---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-21-056202"
form_type: "8-K"
ticker: "RLAY"
cik: "0001812364"
company_name: "Relay Therapeutics, Inc."
filed_at: "2021-11-10T23:59:59+00:00"
generated_at: "2026-06-28T10:10:13.266686+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Relay Therapeutics Q3 net loss $60.8M; cash + offering totals ~$1B, runway into 2025

## Summary
- Net loss $60.8M ($0.66/share) vs $36.1M ($3.00/share) Q3 2020; R&D expenses nearly doubled to $45.0M.
- Cash, equivalents, investments $616.5M at Sept 30, plus $402M net from follow-on offering, providing runway at least into 2025.
- RLY-4008 interim data show selective FGFR2 inhibition; co to select RP2D and start expansion cohorts by end of 2021.
- RLY-2608 preclinical data support it as first allosteric pan-mutant selective PI3Kα inhibitor; combination data at SABCS Dec 2021.
- Follow-on public offering raised $402M gross proceeds, completed after quarter end.

## SEC filing metadata
- accession: 0001564590-21-056202
- form_type: 8-K
- ticker: RLAY
- cik: 0001812364
- company_name: Relay Therapeutics, Inc.
- filed_at: 2021-11-10T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1812364/000156459021056202/0001564590-21-056202-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1812364/000156459021056202/rlay-8k_20211110.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-21-056202
- JSON: https://secwatch.observer/filing/0001564590-21-056202.json
- Plain text: https://secwatch.observer/filing/0001564590-21-056202.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.